These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 11380423)

  • 21. Stimulation of F-cell production in patients with sickle-cell anemia treated with cytarabine or hydroxyurea.
    Veith R; Galanello R; Papayannopoulou T; Stamatoyannopoulos G
    N Engl J Med; 1985 Dec; 313(25):1571-5. PubMed ID: 2415821
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hydroxyurea responses and fetal hemoglobin induction in beta-thalassemia/HbE patients' peripheral blood erythroid cell culture.
    Watanapokasin R; Sanmund D; Winichagoon P; Muta K; Fucharoen S
    Ann Hematol; 2006 Mar; 85(3):164-9. PubMed ID: 16389564
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Efficacy of Rapamycin as Inducer of Hb F in Primary Erythroid Cultures from Sickle Cell Disease and β-Thalassemia Patients.
    Pecoraro A; Troia A; Calzolari R; Scazzone C; Rigano P; Martorana A; Sacco M; Maggio A; Di Marzo R
    Hemoglobin; 2015; 39(4):225-9. PubMed ID: 26016899
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of hydroxyurea on fetal hemoglobin production in vitro.
    Miller BA; Platt O; Hope S; Dover G; Nathan DG
    Blood; 1987 Dec; 70(6):1824-9. PubMed ID: 2445401
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Modulation of gamma globin genes expression by histone deacetylase inhibitors: an in vitro study.
    Ronzoni L; Sonzogni L; Fossati G; Modena D; Trombetta E; Porretti L; Cappellini MD
    Br J Haematol; 2014 Jun; 165(5):714-21. PubMed ID: 24606390
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hydroxyurea exerts bi-modal dose-dependent effects on erythropoiesis in human cultured erythroid cells via distinct pathways.
    Wang M; Tang DC; Liu W; Chin K; Zhu JG; Fibach E; Rodgers GP
    Br J Haematol; 2002 Dec; 119(4):1098-105. PubMed ID: 12472594
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of fetal hemoglobin-inducing agents using the human leukemia KU812 cell line.
    Zein S; Li W; Ramakrishnan V; Lou TF; Sivanand S; Mackie A; Pace B
    Exp Biol Med (Maywood); 2010 Nov; 235(11):1385-94. PubMed ID: 20975082
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Hydroxyurea promotes the reduction of spontaneous BFU-e to normal levels in SS and S/beta thalassemic patients.
    Bincoletto C; Perlingeiro RC; Saad ST; Costa FF; Queiroz ML
    Hemoglobin; 2001 Feb; 25(1):1-7. PubMed ID: 11300342
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of foetal haemoglobin synthesis in erythroid progenitor stem cells: mediated by water-soluble components of Terminalia catappa.
    Aimola IA; Inuwa HM; Nok AJ; Mamman AI
    Cell Biochem Funct; 2014 Jun; 32(4):361-7. PubMed ID: 24470326
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Augmentation by erythropoietin of the fetal-hemoglobin response to hydroxyurea in sickle cell disease.
    Rodgers GP; Dover GJ; Uyesaka N; Noguchi CT; Schechter AN; Nienhuis AW
    N Engl J Med; 1993 Jan; 328(2):73-80. PubMed ID: 7677965
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Resveratrol, a remarkable inhibitor of ribonucleotide reductase.
    Fontecave M; Lepoivre M; Elleingand E; Gerez C; Guittet O
    FEBS Lett; 1998 Jan; 421(3):277-9. PubMed ID: 9468322
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combined use of nonmyelosuppressive nitrosourea analogues with hydroxyurea in the induction of F-cell production in a human erythroleukemic cell line.
    Iyamu EW; Adunyah SE; Fasold H; Horiuchi K; Baliga S; Ohene-Frempong K; Turner EA; Asakura T
    Exp Hematol; 2003 Jul; 31(7):592-600. PubMed ID: 12842704
    [TBL] [Abstract][Full Text] [Related]  

  • 33. p21Cip1 gene expression is modulated by Egr1: a novel regulatory mechanism involved in the resveratrol antiproliferative effect.
    Ragione FD; Cucciolla V; Criniti V; Indaco S; Borriello A; Zappia V
    J Biol Chem; 2003 Jun; 278(26):23360-8. PubMed ID: 12690110
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Spectrum of fetal hemoglobin responses in sickle cell patients treated with hydroxyurea: the National Institutes of Health experience.
    Rodgers GP
    Semin Oncol; 1992 Jun; 19(3 Suppl 9):67-73. PubMed ID: 1379375
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Myelodysplastic syndrome with clonal cytogenetic abnormalities followed by fatal erythroid leukemia after 14 years of exposure to hydroxyurea for sickle cell anemia.
    Aumont C; Driss F; Lazure T; Picard V; Creidy R; De Botton S; Saada V; Lambotte O; Bilhou-Nabera C; Tertian G; Michot JM
    Am J Hematol; 2015 Jul; 90(7):E131-2. PubMed ID: 25801602
    [No Abstract]   [Full Text] [Related]  

  • 36. Negative regulation of quinone reductase 2 by resveratrol in cultured vascular smooth muscle cells.
    Cai JB; Zhang ZH; Xu DJ; Qian ZY; Wang ZR; Huang YZ; Zou JG; Cao KJ
    Clin Exp Pharmacol Physiol; 2008 Dec; 35(12):1419-25. PubMed ID: 18671725
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hydroxyurea induces a senescence-like change of K562 human erythroleukemia cell.
    Park JI; Jeong JS; Han JY; Kim DI; Gao YH; Park SC; Rodgers GP; Kim IH
    J Cancer Res Clin Oncol; 2000 Aug; 126(8):455-60. PubMed ID: 10961388
    [TBL] [Abstract][Full Text] [Related]  

  • 38. RN-1, a potent and selective lysine-specific demethylase 1 inhibitor, increases γ-globin expression, F reticulocytes, and F cells in a sickle cell disease mouse model.
    Rivers A; Vaitkus K; Ruiz MA; Ibanez V; Jagadeeswaran R; Kouznetsova T; DeSimone J; Lavelle D
    Exp Hematol; 2015 Jul; 43(7):546-53.e1-3. PubMed ID: 25931013
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Modulation of HBF production by erythropoietin.
    Stamatoyannopoulos G; Umemura T; al-Khatti A; Spadaccino E; Abels RI; Fritsch EF; Papayannopoulou T
    Prog Clin Biol Res; 1989; 316B():269-80. PubMed ID: 2482497
    [No Abstract]   [Full Text] [Related]  

  • 40. Hydroxyurea and sickle cell anemia. Clinical utility of a myelosuppressive "switching" agent. The Multicenter Study of Hydroxyurea in Sickle Cell Anemia.
    Charache S; Barton FB; Moore RD; Terrin ML; Steinberg MH; Dover GJ; Ballas SK; McMahon RP; Castro O; Orringer EP
    Medicine (Baltimore); 1996 Nov; 75(6):300-26. PubMed ID: 8982148
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.